AQB Share Price | AquaBounty Technologies, Inc. Stock Analysis & Recommendation

Q: How big is AquaBounty Technologies, Inc.?

Market Cap: As of Jun 18, AquaBounty Technologies, Inc. has a market capitalization of 2.92 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, AquaBounty Technologies, Inc. reported net sales of 0.71 million and a net profit of -64.46 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 15.84 million and total assets of 34.06 million.

Q: What does AquaBounty Technologies, Inc. do?

Overview: AquaBounty Technologies, Inc. is engaged in the research, development, and commercialization of antifreeze proteins and focuses on managing aquaculture productivity within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Net Profit: 1 Million (Quarterly Results - Mar 2025) Market Cap: USD 2.92 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.01 Return on Equity: -104.55% Price to Book: 0.17Contact Details: Address: 2 Clock Tower Pl Ste 395, MAYNARD MA: 01754-2539 Tel: 1 978 6486000 Website: https://aquabounty.com/

Q: Is AquaBounty Technologies, Inc. overvalued or undervalued?

As of 15 May 2025, AquaBounty Technologies, Inc. has moved from a grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, particularly given its negative performance metrics. Key ratios include a price to book value of 0.18, an EV to EBIT of -0.18, and an EV to EBITDA of -0.19, all of which reflect a troubling financial situation.In comparison to its peers, AquaBounty's financial ratios are significantly worse than those of Catalyst Biosciences, Inc., which has a P/E ratio of 90.02, and Elutia, Inc., which is rated risky with an EV to EBITDA of -4.64. Additionally, AquaBounty's return on capital employed (ROCE) stands at a staggering -93.65%, and its return on equity (ROE) is at -104.55%, further emphasizing its struggles. The company's stock has underperformed relative to the S&P 500, particularly over the past year, where it has declined by 54.53% compared to the index's increase of 10.26%.

Q: Is AquaBounty Technologies, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for AquaBounty Technologies, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by weekly MACD and KST indicators showing bullish signals, along with bullish readings from Bollinger Bands and On-Balance Volume. Daily moving averages also confirm a bullish trend. However, the weekly RSI is bearish, indicating some short-term weakness. In terms of performance, AquaBounty has significantly outperformed the S&P 500 over the past week and month, with returns of 29.57% and 107.00% respectively, compared to the S&P 500's 1.05% and 2.33%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

830

Shareholding (Dec 2025)

FII

0.01%

Held by 7 FIIs

DII

98.23%

Held by 2 DIIs

Promoter

0.00%

How big is AquaBounty Technologies, Inc.?

22-Jun-2025

As of Jun 18, AquaBounty Technologies, Inc. has a market capitalization of 2.92 million, with net sales of 0.71 million and a net profit of -64.46 million over the latest four quarters. The company reported shareholder's funds of 15.84 million and total assets of 34.06 million as of Dec 24.

View full answer

What does AquaBounty Technologies, Inc. do?

22-Jun-2025

AquaBounty Technologies, Inc. focuses on the research and commercialization of antifreeze proteins to enhance aquaculture productivity. It is a micro-cap company with a market cap of $2.92 million and reported a net profit of $1 million in March 2025.

View full answer

Who are in the management team of AquaBounty Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of AquaBounty Technologies, Inc. includes Non-Executive Independent Chairman Richard Clothier, CEO Sylvia Wulf, and Non-Executive Directors Rick Sterling, Richard Huber, Christine St.Clare, and James Turk. They guide the company's strategic direction.

View full answer

Is AquaBounty Technologies, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2025, AquaBounty Technologies, Inc. is considered overvalued with troubling financial metrics, including a price to book value of 0.18 and a return on equity of -104.55%, and has significantly underperformed the S&P 500, declining by 54.53% over the past year.

View full answer

Is AquaBounty Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, AquaBounty Technologies, Inc. has shifted to a bullish trend, supported by positive indicators like MACD and Bollinger Bands, despite a bearish weekly RSI, and has outperformed the S&P 500 with returns of 29.57% and 107.00% over the past week and month, respectively.

View full answer

Compare AquaBounty Technologies, Inc. with Similar Stocks

Elutia, Inc.Orgenesis, Inc.NeuroBo Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.57

Return on Equity

-59.76%

Price to Book

0.28

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.49%

6 Months

-10.48%

1 Year

36.83%

2 Years

-48.07%

3 Years

74.72%

4 Years

-29.85%

5 Years

-99.12%

AquaBounty Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.23%

EBIT Growth (5y)

8.99%

EBIT to Interest (avg)

-18.93

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.01

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.87%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.28

EV to EBIT

-1.64

EV to EBITDA

-1.68

EV to Capital Employed

0.54

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-33.09%

ROE (Latest)

-59.76%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.76%)

Foreign Institutions

Held by 7 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -145.00% vs 233.33% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "2.00",
          "chgp": "-145.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 80.70% vs 17.39% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-8.50",
          "chgp": "52.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "1.70",
          "chgp": "-88.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "-0.20",
          "chgp": "1,100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-11.40",
          "chgp": "80.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.60

0.00

Interest

0.30

0.00

Exceptional Items

0.00

1.30

-100.00%

Consolidate Net Profit

-0.90

2.00

-145.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -145.00% vs 233.33% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.00

-8.50

52.94%

Interest

0.20

1.70

-88.24%

Exceptional Items

2.00

-0.20

1,100.00%

Consolidate Net Profit

-2.20

-11.40

80.70%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 80.70% vs 17.39% in Dec 2024

All Annual Results

Company CV

About AquaBounty Technologies, Inc.

AquaBounty Technologies, Inc.

Pharmaceuticals & Biotechnology

AquaBounty Technologies, Inc. is a engaged in research, development and commercialization of the commercial viability of a group of proteins, antifreeze proteins (AFPs). The Company focuses on the managing aquaculture productivity. It offers AquAdvantage Salmon (AAS), which can be grown in contained, land-based facilities. It offers AquAdvantage Salmon for land-based facilities that can be built closer to consumers to manage the need for air freight shipping and transportation. The Company's subsidiaries include AquaBounty Canada, Inc., which operates a commercial biotechnology laboratory that conducts research and development programs related to the Company's technologies; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC, and AquaBounty Brasil Participacoes Ltda., which conducts commercial trials of the Company's AquAdvantage Salmon.

Company Coordinates

Company Details

2 Clock Tower Pl Ste 395 , MAYNARD MA : 01754-2539

Tel: 1 978 6486000

https://aquabounty.com/

Registrar Details